Andrew Asher Protter,Sarvajit Chakravarty,Rajendra Parasmal Jain,Michael John Green
申请号：
US13789361
公开号：
US09006263B2
申请日:
2013.03.07
申请国别(地区):
US
年份:
2015
代理人:
摘要：
Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α2B antagonists. The compounds may also bind to and antagonize adrenergic receptor α1B. The compounds may find use in therapy, e.g., to (i) reduce blood pressure and/or (ii) promote renal blood flow and/or (iii) decrease or inhibit sodium reabsorption. The compounds may also be used to treat diseases or conditions that are, or are expected to be, responsive to a decrease in blood pressure. Use of the compounds to treat cardiovascular and renal disorders is particularly described.
